Immunoblot_NP Analysis_NP of_IN the_DT Humoral_NP Immune_NP Response_NP to_TO Leishmania_NP donovani_NP Polypeptides_NP in_IN Cases_NPS of_IN Human_NP Visceral_NP Leishmaniasis_NP :_: Its_PP$ Usefulness_NN in_IN Prognosis_NP Sera_NP from_IN Indian_JJ patients_NNS with_IN parasitologically_RB confirmed_VBN visceral_JJ leishmaniasis_NN were_VBD studied_VBN by_IN immunoblot_NN analysis_NN in_IN order_NN to_TO identify_VB a_DT specific_JJ pattern_NN for_IN Leishmania_NP infection_NN ._SENT A_DT soluble_JJ extract_NN of_IN Leishmania_NP donovani_NP was_VBD used_VBN as_IN antigen_NN ._SENT At_IN diagnosis_NN the_DT sera_NN from_IN patients_NNS with_IN visceral_JJ leishmaniasis_NN specifically_RB recognized_VBN fractions_NNS represented_VBN by_IN bands_NNS of_IN 201_CD kDa_NNS (_( 50_CD %_NN of_IN serum_NN samples_NNS )_) ,_, 193_CD kDa_NNS (_( 60_CD %_NN )_) ,_, 147_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 120_CD kDa_NNS (_( 60_CD %_NN )_) ,_, 100_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 80_CD kDa_NNS (_( 80_CD %_NN )_) ,_, 70_CD kDa_NNS (_( 70_CD %_NN )_) ,_, 65_CD kDa_NNS (_( 100_CD %_NN )_) ,_, 50_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 36_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 20_CD kDa_NNS (_( 70_CD %_NN )_) ,_, and_CC 18_CD kDa_NNS (_( 50_CD %_NN )_) ._SENT The_DT 65-kDa_JJ band_NN ,_, common_JJ to_TO all_DT patients_NNS infected_VBN with_IN Leishmania_NP parasites_NNS ,_, was_VBD found_VBN at_IN the_DT time_NN of_IN diagnosis_NN ._SENT However_RB ,_, the_DT immunoblot_NN pattern_NN changed_VBN after_IN patients_NNS were_VBD treated_VBN and_CC cured_VBN with_IN sodium_NN antimony_NN gluconate_NN (_( SAG_NP ;_: n_NN =10_NN )_) or_CC miltefosine_JJ (_( n_NN =10_NN )_) ,_, as_RB was_VBD evident_JJ from_IN blots_NNS of_IN sera_NN obtained_VBN pretreatment_NN and_CC at_IN 1_CD ,_, 3_CD ,_, and_CC 6_CD months_NNS posttreatment_NN ._SENT At_IN 6_CD months_NNS posttreatment_NN ,_, immunoblots_NNS of_IN sera_NN from_IN patients_NNS on_IN the_DT SAG_NP regimen_NN showed_VBD the_DT disappearance_NN of_IN all_DT bands_NNS except_IN the_DT 70-kDa_NP band_NN ._SENT Similarly_RB ,_, sera_NN from_IN those_DT on_IN the_DT miltefosine_NN regimen_NN showed_VBD the_DT disappearance_NN of_IN all_DT bands_NNS except_IN the_DT 65-_CD and_CC 70-kDa_NP bands_NNS ._SENT This_DT study_NN shows_VBZ that_IN Western_JJ blot_NN analysis_NN is_VBZ a_DT sensitive_JJ test_NN for_IN detection_NN of_IN anti-Leishmania_NN antibodies_NNS ._SENT Moreover_RB ,_, the_DT persistence_NN of_IN reactivity_NN with_IN the_DT 65-_CD and_CC 70-kDa_NP bands_NNS in_IN the_DT sera_NN of_IN all_DT groups_NNS shows_VBZ its_PP$ promise_NN as_IN a_DT diagnostic_JJ and_CC prognostic_JJ tool_NN ._SENT Human_JJ visceral_JJ leishmaniasis_NN is_VBZ caused_VBN by_IN a_DT protozoan_JJ parasite_NN of_IN the_DT Leishmania_NP donovani_NN complex_NN ,_, namely_RB ,_, Leishmania_NP donovani_NP ._SENT This_DT infection_NN is_VBZ characterized_VBN clinically_RB by_IN fever_NN ,_, hepatosplenomegaly_RB ,_, anemia_NN ,_, and_CC weight_NN loss_NN ._SENT A_DT marked_JJ hypergammaglobulinemia_NN and_CC absence_NN of_IN detectable_JJ cell-mediated_JJ immunity_NN are_VBP the_DT principal_JJ immunological_JJ features_NNS of_IN the_DT disease_NN ._SENT Although_IN patients_NNS generate_VBP high_JJ levels_NNS of_IN nonspecific_JJ immunoglobulin_NN as_RB well_RB as_IN specific_JJ antileishmanial_JJ antibodies_NNS ,_, they_PP fail_VBP to_TO respond_VB to_TO parasite_NN antigen_NN in_IN the_DT delayed-type_NN hypersensitivity_NN skin_NN test_NN ._SENT A_DT kinesin-related_JJ protein-encoding_NN gene_NN has_VBZ been_VBN discovered_VBN in_IN Leishmania_NP chagasi_NP and_CC contains_VBZ a_DT repetitive_JJ 117-bp_JJ sequence_NN encoding_VBG 39_CD amino_NN acid_JJ residues_NNS (_( K39_NP )_) conserved_VBD at_IN the_DT C-terminal_JJ end_NN in_IN all_DT of_IN the_DT visceral_JJ leishmaniasis-causing_NN isolates_NNS examined_VBD so_RB far_RB ._SENT The_DT recombinant_JJ product_NN of_IN K39_NP (_( rK39_NN )_) has_VBZ proved_VBN to_TO be_VB a_DT very_RB sensitive_JJ and_CC specific_JJ antigen_NN in_IN an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) for_IN the_DT serodiagnosis_NN of_IN visceral_JJ leishmaniasis_NN from_IN the_DT foci_NNS of_IN endemicity_NN in_IN Brazil_NP ,_, China_NP ,_, Pakistan_NP ,_, and_CC Sudan_NP ._SENT Kumar_NP et_FW al._FW reported_VBD extremely_RB high_JJ levels_NNS of_IN anti-rK39_JJ antibodies_NNS in_IN patients_NNS with_IN visceral_JJ leishmaniasis_NN ,_, suggesting_VBG the_DT application_NN of_IN rK39_NN for_IN a_DT sensitive_JJ and_CC specific_JJ means_NNS of_IN serodiagnosis_NN and_CC the_DT potential_NN of_IN rK39_NP ELISA_NP in_IN the_DT monitoring_NN of_IN drug_NN therapy_NN and_CC the_DT detection_NN of_IN disease_NN relapses_NNS ._SENT To_TO date_NN ,_, several_JJ L._NP donovani-specific_JJ proteins_NNS ,_, including_VBG species-specific_JJ and_CC subspecies-specific_JJ molecules_NNS ,_, have_VBP been_VBN identified_VBN with_IN monoclonal_NN antibodies_NNS or_CC polyvalent_JJ antisera_NN ._SENT Several_JJ of_IN these_DT proteins_NNS elicit_VBP a_DT strong_JJ humoral_JJ immune_JJ response_NN during_IN visceral_JJ leishmaniasis_NN ,_, allowing_VBG the_DT specific_JJ diagnosis_NN of_IN visceral_JJ leishmaniasis_NN by_IN a_DT competitive_JJ ELISA_NP or_CC a_DT direct_JJ dot_NN blot_NN assay_NN ._SENT Immunoblots_NNS have_VBP been_VBN useful_JJ in_IN studies_NNS of_IN host_NN serological_JJ responses_NNS during_IN infection_NN ,_, and_CC a_DT few_JJ antigens_NNS with_IN potential_JJ diagnostic_JJ value_NN have_VBP been_VBN selected_VBN ._SENT The_DT humoral_JJ immune_JJ response_NN occurs_VBZ during_IN the_DT active_JJ phase_NN of_IN infection_NN ,_, with_IN the_DT appearance_NN of_IN low_JJ titers_NNS of_IN antibodies_NNS that_WDT disappear_VBP some_DT months_NNS after_IN the_DT end_NN of_IN treatment_NN representing_VBG a_DT temporary_JJ response_NN ._SENT This_DT fact_NN has_VBZ made_VBN the_DT assessment_NN of_IN antibody_NN titers_NNS a_DT useful_JJ tool_NN for_IN patient_JJ follow-up_NN after_IN therapy_NN and_CC for_IN defining_VBG the_DT period_NN during_IN which_WDT clinicians_NNS should_MD observe_VB patients_NNS in_IN order_NN to_TO make_VB a_DT prognosis_NN ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP have_VBP examined_VBN patients_NNS '_POS antibody_NN responses_NNS at_IN the_DT time_NN of_IN diagnosis_NN and_CC various_JJ stages_NNS posttreatment_NN using_VBG the_DT immunoblot_NN technique_NN with_IN soluble_JJ L._NP donovani_NN antigen_NN ._SENT We_PP had_VBD the_DT double_JJ objective_NN of_IN identifying_VBG a_DT particular_JJ band_NN pattern_NN present_JJ in_IN the_DT patients_NNS affected_VBN by_IN visceral_JJ leishmaniasis_NN (_( confirmed_VBN by_IN the_DT presence_NN of_IN parasites_NNS in_IN a_DT sample_NN taken_VBN from_IN the_DT spleen_NN )_) and_CC describing_VBG any_DT possible_JJ variation_NN in_IN this_DT band_NN pattern_NN following_VBG antileishmanial_JJ therapy_NN with_IN sodium_NN antimony_NN gluconate_NN (_( SAG_NP )_) or_CC miltefosine_NN ._SENT Antigen_NN ._SENT |_SYM L._NP donovani_NP (_( MHOM/IN/96/B.H.U.70_NP )_) promastigotes_NNS were_VBD cultivated_VBN in_IN tissue_NN culture_NN flasks_NNS with_IN RPMI_NP 1640_CD medium_NN (_( Hi-Media_NP ,_, Mumbai_NP ,_, India_NP )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN (_( Gibco_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) and_CC antibiotics_NNS (_( gentamicin_NN )_) ._SENT Parasites_NNS were_VBD taken_VBN at_IN the_DT late-logarithmic_JJ phase_NN of_IN growth_NN ,_, washed_VBD five_CD times_NNS at_IN 4C_JJ with_IN sterile_JJ phosphate-buffered_JJ saline_NN (_( PBS_NP )_) ,_, and_CC centrifuged_VBD at_IN 1,400_CD x_NN g_NN for_IN 15_CD min_NN ._SENT The_DT parasite_NN pellet_NN was_VBD resuspended_VBN in_IN 1_CD ml_NN of_IN PBS_NP ,_, and_CC the_DT mixture_NN was_VBD immediately_RB frozen_VBN at_IN -70C_NN ._SENT In_IN order_NN to_TO make_VB up_RP only_RB one_CD batch_NN of_IN antigen_NN for_IN Western_JJ blot_NN analysis_NN ,_, all_DT parasites_NNS were_VBD kept_VBN frozen_VBN at_IN this_DT temperature_NN until_IN there_EX were_VBD sufficient_JJ parasites_NNS from_IN which_WDT soluble_JJ antigen_NN could_MD be_VB obtained_VBN ._SENT To_TO prepare_VB the_DT soluble_JJ antigen_NN ,_, a_DT method_NN described_VBN by_IN Isaza_NP et_FW al._FW was_VBD used_VBN ,_, with_IN slight_JJ modifications_NNS ._SENT Briefly_RB ,_, the_DT parasites_NNS were_VBD defrosted_VBN and_CC resuspended_VBN in_IN 2_CD ml_NN of_IN lysis_NN buffer_NN (_( 20_CD mM_NP Tris_NP HCl_NP [_SYM pH_NN 7.4_CD ]_SYM containing_VBG 40_CD mM_NP NaCl_NP ,_, 10_CD mM_NP EDTA_NP ,_, 2_CD mM_NP phenylmethylsufonyl_JJ fluoride_NN [_SYM BDH_NP ,_, Mumbai_NP ,_, India_NP ]_SYM ,_, and_CC 0.4_CD %_NN sodium_NN dodecyl_JJ sulfate_NN [_SYM BDH_NP ]_SYM )_) ._SENT The_DT mixture_NN was_VBD left_VBN on_IN ice_NN for_IN 30_CD min_NN ,_, with_IN vortex_NN agitation_NN every_DT 10_CD min_NN ._SENT It_PP was_VBD then_RB centrifuged_VBN at_IN 6,000_CD x_NN g_NN for_IN 20_CD min_NN at_IN 4C_JJ ._SENT The_DT supernatant_JJ was_VBD removed_VBN and_CC kept_VBN at_IN -70C_NN until_IN use_NN ._SENT A_DT small_JJ sample_NN was_VBD used_VBN for_IN protein_NN determination_NN by_IN a_DT method_NN modified_VBN from_IN that_DT of_IN Lowry_NP et_FW al._FW ._SENT By_IN this_DT method_NN the_DT final_JJ antigen_NN protein_NN concentration_NN was_VBD found_VBN to_TO be_VB 9.4_CD mg/ml_NN ._SENT Human_JJ sera_NN ._SENT |_SYM Serum_NP samples_NNS were_VBD collected_VBN from_IN patients_NNS with_IN parasitologically_RB confirmed_VBN visceral_JJ leishmaniasis_NN (_( kala_NP azar_NP )_) (_( L._NP donovani_NP body_NN score_NN in_IN splenic_JJ aspirate_NN of_IN 2+_JJ to_TO 4+_JJ ,_, i.e._FW ,_, between_IN >1_NN to_TO 10_CD parasites/100_NN field_NN and_CC >1_NN to_TO 10_CD parasites/field_NN )_) at_IN the_DT time_NN of_IN diagnosis_NN ._SENT Sera_NP were_VBD obtained_VBN by_IN venipuncture_NN from_IN patients_NNS and_CC controls_NNS registered_VBN at_IN Kala-azar_NP Medical_NP Research_NP Centre_NP ,_, Muzaffarpur_NP ,_, India_NP ,_, and_CC Sir_NP Sundar_NP Lal_NP Hospital_NP ,_, Banaras_NP Hindu_NP University_NP ,_, Varanasi_NP ,_, India_NP ._SENT Blood_NN was_VBD allowed_VBN to_TO coagulate_VB at_IN room_NN temperature_NN and_CC was_VBD then_RB centrifuged_VBN at_IN 1,400_CD x_NN g_NN for_IN 5_CD min_NN ._SENT All_DT sera_NN were_VBD stored_VBN at_IN -70C_NN until_IN required_VBN ._SENT Western_JJ blot_NN analysis_NN ._SENT |_SYM SDS-polyacrylamide_NP gel_NN electrophoresis_NN was_VBD done_VBN with_IN a_DT vertical_JJ (_( Bangalore_NP Genei_NP ,_, Peenya_NP Bangalore_NP ,_, India_NP )_) gel_NN apparatus_NN ._SENT The_DT antigen_NN was_VBD boiled_VBN for_IN 5_CD min_NN in_IN sample_NN buffer_NN (_( two_CD times_NNS )_) and_CC was_VBD immediately_RB subjected_VBN to_TO electrophoresis_NN in_IN an_DT SDS-10_NP %_NN polyacrylamide_NN gel_NN containing_VBG 0.1_CD %_NN SDS_NP as_RB described_VBD by_IN Laemmli_NP ._SENT The_DT slab_NN gel_NN was_VBD run_VBN with_IN two_CD lanes_NNS per_IN comb_NNS :_: a_DT 100-mm_NP lane_NN for_IN the_DT parasite_NN antigen_NN sample_NN and_CC a_DT 7-mm_NP lane_NN for_IN a_DT wide-range_JJ molecular_JJ mass_NN marker_NN (_( kind_NN gift_NN of_IN David_NP Sacks_NP ,_, National_NP Institute_NP of_IN Allergy_NP and_CC Infectious_NP Diseases_NPS ,_, National_NP Institutes_NPS of_IN Health_NP ,_, Bethesda_NP ,_, Md._NP )_) ._SENT Three_CD hundred_CD micrograms_NNS of_IN protein_NN was_VBD used_VBN for_IN gel_NN electrophoresis_NN ._SENT The_DT gels_NNS were_VBD run_VBN at_IN 15_CD mA_NNS in_IN the_DT stacking_VBG gel_NN and_CC 30_CD mA_NNS in_IN the_DT resolving_VBG gel_NN until_IN the_DT bromophenol_NN blue_JJ dye_NN migrated_VBD 1_CD cm_NN from_IN the_DT bottom_NN of_IN the_DT gel_NN in_IN Tris-glycine-SDS_NP buffer_NN (_( pH_NN 8.3_CD )_) ._SENT Immunoblotting_NP ._SENT |_SYM Transfer_NN of_IN polypeptides_NNS from_IN SDS-polyacrylamide_NN gels_NNS onto_IN nitrocellulose_NN membrane_NN (_( pore_NN size_NN ,_, 0.45_CD mum_NN ;_: kind_NN gift_NN of_IN R._NP T._NP Kenney_NP ,_, Center_NP for_IN Biologics_NP Evaluation_NP and_CC Research_NP ,_, Food_NP and_CC Drug_NP Administration_NP ,_, Rockville_NP ,_, Md._NP )_) was_VBD done_VBN in_IN a_DT transblotting_JJ chamber_NN at_IN 4_CD V/cm_NP and_CC 4C_JJ for_IN overnight_JJ in_IN 25_CD mM_NP Tris-192_NP mM_NP glycine-20_NN %_NN (_( vol/vol_NN )_) methanol_NN ._SENT Following_VBG the_DT blotting_VBG ,_, the_DT membranes_NNS were_VBD stained_VBN with_IN 0.5_CD %_NN ponceau_NN red_NN for_IN 5_CD min_NN and_CC were_VBD destained_VBN with_IN distilled_JJ water_NN ._SENT The_DT blotted_VBN gels_NNS were_VBD stained_VBN with_IN Coomassie_NP brilliant_JJ blue_NN in_IN order_NN to_TO make_VB sure_JJ that_IN all_DT polypeptides_NNS had_VBD been_VBN completely_RB transferred_VBN ._SENT Detection_NN of_IN antibodies_NNS from_IN patients_NNS '_POS sera_NN bound_VBN to_TO antigens_NNS was_VBD done_VBN with_IN a_DT 5-bromo-4-chloro-3-indolylphosphate-Nitro_NP Blue_NP Tetrazolium_NP system_NN (_( BCIP-NBT_NP ;_: Kirkegaard_NP &_CC Perry_NP Laboratories_NPS ,_, Gaithersburg_NP ,_, Md._NP )_) ._SENT Four-millimeter-wide_JJ strips_NNS were_VBD cut_VBN from_IN the_DT previously_RB blotted_VBN membrane_NN and_CC blocked_VBN in_IN 5_CD %_NN bovine_JJ serum_NN albumin-0.3_NN %_NN Tween_NP 20_CD in_IN 100_CD mM_NP Tris-buffered_NP saline_NN (_( TBS_NP ;_: pH_NN 7.4_CD )_) for_IN an_DT hour_NN at_IN room_NN temperature_NN ._SENT After_IN six_CD washes_VBZ of_IN 15_CD min_NN each_DT in_IN TBS-0.1_NP %_NN Tween_NP 20_CD ,_, the_DT strips_NNS were_VBD incubated_VBN with_IN serum_NN (_( diluted_VBN 1:100_CD in_IN 1_CD %_NN bovine_JJ serum_NN albumin-TBS_NNS )_) for_IN 2_CD h_NN at_IN 37C_JJ with_IN constant_JJ stirring_VBG ._SENT After_IN incubation_NN with_IN the_DT primary_JJ antibody_NN ,_, the_DT strips_NNS were_VBD washed_VBN four_CD times_NNS for_IN 15_CD min_NN each_DT time_NN with_IN Tween_NP 20-TBS_NNS ._SENT After_IN the_DT last_JJ wash_NN ,_, immune_JJ complexes_NNS were_VBD detected_VBN with_IN a_DT 1:500_CD dilution_NN of_IN alkaline_JJ phosphatase_NN (_( Bangalore_NP Genei_NP )_) conjugated_VBD with_IN goat_NN anti-human_NN immunoglobulin_NN G_NP (_( IgG_NP )_) ,_, and_CC the_DT mixture_NN was_VBD incubated_VBN with_IN constant_JJ shaking_VBG for_IN 2_CD h_NN at_IN room_NN temperature_NN ._SENT After_IN incubation_NN the_DT membrane_NN was_VBD washed_VBN with_IN Tween_NP 20-TBS_NP three_CD or_CC four_CD times_NNS and_CC then_RB washed_VBN with_IN TBS_NP only_RB to_TO remove_VB the_DT Tween_NP 20_CD ._SENT The_DT membranes_NNS were_VBD developed_VBN with_IN the_DT BCIP-NBT_NP system_NN (_( Kirkegaard_NP &_CC Perry_NP Laboratories_NPS )_) for_IN 5_CD min_NN ._SENT The_DT reaction_NN was_VBD stopped_VBN with_IN PBS-EDTA_NP (_( 20_CD mM_NP EDTA_NP )_) ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Analysis_NN of_IN the_DT corresponding_JJ polypeptides_NNS in_IN the_DT blotted_VBN membranes_NNS was_VBD done_VBN by_IN using_VBG an_DT exponential_JJ regression_NN curve_NN with_IN the_DT molecular_JJ mass_NN markers_NNS of_IN each_DT membrane_NN ,_, calculating_VBG the_DT relative_JJ mobility_NN (_( Rf_NP )_) of_IN each_DT protein_NN ,_, and_CC looking_VBG for_IN its_PP$ corresponding_JJ molecular_JJ mass_NN ._SENT Study_NN population_NN ._SENT |_SYM The_DT clinical_JJ and_CC laboratory_NN features_NNS of_IN the_DT visceral_JJ leishmaniasis_NN patients_NNS on_IN admission_NN are_VBP summarized_VBN in_IN Table_NP ._SENT The_DT response_NN to_TO SAG_NP or_CC miltefosine_JJ therapy_NN was_VBD prompt_JJ ,_, and_CC the_DT splenic_JJ aspirate_JJ smears_NNS of_IN all_DT patients_NNS showed_VBD no_DT parasites_NNS (_( L._NP donovani_NP bodies_NNS )_) at_IN the_DT end_NN of_IN treatment_NN (_( the_DT patients_NNS were_VBD parasitologically_RB cured_VBN )_) ._SENT These_DT patients_NNS were_VBD subsequently_RB monitored_VBN ._SENT Pretreatment_NN sera_NN ._SENT |_SYM In_IN general_NN ,_, the_DT sera_NN from_IN patients_NNS (_( n_NN =_SYM 10_CD )_) with_IN visceral_JJ leishmaniasis_NN specifically_RB recognized_VBN polypeptides_NNS ranging_VBG from_IN 18_CD to_TO more_JJR than_IN 201_CD kDa_NN ,_, with_IN the_DT frequently_RB occurring_VBG bands_NNS being_JJ of_IN 201_CD kDa_NNS (_( 50_CD %_NN of_IN serum_NN samples_NNS )_) ,_, 193_CD kDa_NNS (_( 60_CD %_NN )_) ,_, 147_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 120_CD kDa_NNS (_( 60_CD %_NN )_) ,_, 100_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 80_CD kDa_NNS (_( 80_CD %_NN )_) ,_, 70_CD kDa_NNS (_( 70_CD %_NN )_) ,_, 65_CD kDa_NNS (_( 100_CD %_NN )_) ,_, 50_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 36_CD kDa_NNS (_( 50_CD %_NN )_) ,_, 20_CD kDa_NNS (_( 70_CD %_NN )_) ,_, and_CC 18_CD kDa_NNS (_( 50_CD %_NN )_) ._SENT We_PP found_VBD one_CD band_NN of_IN 65_CD kDa_NN in_IN sera_NN from_IN 100_CD %_NN of_IN patients_NNS with_IN active_JJ disease_NN ._SENT Immunoblot_NN evaluation_NN ._SENT (_( i_NP )_) SAG_NP treatment_NN group_NN ._SENT |_SYM We_PP studied_VBD the_DT sera_NN of_IN patients_NNS (_( n_NN =_SYM 10_CD )_) who_WP were_VBD being_VBG treated_VBN with_IN SAG_NP ._SENT We_PP did_VBD antibody_NN tests_NNS at_IN regular_JJ intervals_NNS for_IN up_IN to_TO 6_CD months_NNS posttreatment_NN ._SENT All_DT patients_NNS were_VBD cured_VBN after_IN the_DT end_NN of_IN treatment_NN ,_, as_RB confirmed_VBN by_IN laboratory_NN and_CC parasitological_JJ tests_NNS ._SENT At_IN 1_CD month_NN after_IN treatment_NN ,_, the_DT bands_NNS of_IN 201_CD ,_, 193_CD ,_, 100_CD ,_, and_CC 36_CD kDa_NNS disappeared_VBD ._SENT At_IN 3_CD and_CC 6_CD months_NNS posttreatment_NN all_DT bands_NNS except_IN the_DT 70-kDa_NP band_NN disappeared_VBD ._SENT (_( ii_NP )_) Miltefosine_NP treatment_NN group_NN ._SENT |_SYM We_PP also_RB studied_VBD patients_NNS (_( n_NN =_SYM 10_CD )_) who_WP were_VBD being_VBG treated_VBN with_IN the_DT oral_JJ drug_NN miltefosine_NN ._SENT We_PP compared_VBD pretreatment_NN sera_NN with_IN sera_NN obtained_VBN at_IN 1_CD ,_, 3_CD ,_, and_CC 6_CD months_NNS posttreatment_NN ._SENT At_IN 1_CD month_NN posttreatment_NN only_RB the_DT 20-_CD and_CC 80-kDa_JJ bands_NNS had_VBD disappeared_VBN ._SENT At_IN 3_CD months_NNS posttreatment_NN all_DT bands_NNS except_IN the_DT bands_NNS at_IN 36_CD ,_, 65_CD ,_, and_CC 70_CD kDa_NNS had_VBD disappeared_VBN ;_: and_CC at_IN 6_CD months_NNS posttreatment_NN all_DT bands_NNS except_IN the_DT 65-_CD and_CC 70-kDa_NP bands_NNS had_VBD disappeared_VBN ._SENT The_DT 65-_CD and_CC 70-kDa_NP bands_NNS remained_VBD at_IN all_DT time_NN points_NNS ._SENT Sera_NN from_IN all_DT patients_NNS had_VBD antibodies_NNS to_TO the_DT 65-_CD and_CC 70-kDa_NP bands_NNS in_IN common_JJ at_IN pretreatment_NN and_CC 1_CD ,_, 3_CD ,_, and_CC 6_CD months_NNS (_( follow_VB up_RP )_) posttreatment_NN ._SENT Interestingly_RB ,_, all_DT patients_NNS in_IN both_CC the_DT SAG_NP and_CC miltefosine_JJ treatment_NN groups_NNS showed_VBD the_DT exact_JJ same_JJ response_NN pattern_NN after_IN treatment_NN and_CC follow-up_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Immunoblotting_NP with_IN L._NP donovani_NP Immunoblotting_NP with_IN L._NP donovani_NP soluble_JJ antigen_NN with_IN the_DT alkaline_JJ phosphatase_NN system_NN ._SENT VL_NP lanes_NNS 1_CD to_TO 10_CD ,_, sera_NN from_IN patients_NNS with_IN visceral_JJ leishmaniasis_NN at_IN the_DT time_NN of_IN diagnosis_NN ;_: EC_NP lanes_NNS 1_CD to_TO 3_CD ,_, sera_NN from_IN controls_NNS from_IN an_DT area_NN of_IN endemicity_NN ;_: and_CC NEC_NP lanes_NNS 1_CD to_TO 3_CD ,_, sera_NN from_IN controls_NNS from_IN an_DT area_NN of_IN nonendemicity_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Immunoblotting_NN with_IN soluble_JJ L._NP donovani_NN Immunoblotting_NN with_IN soluble_JJ L._NP donovani_NN antigen_NN with_IN the_DT alkaline_JJ phosphatase_NN system_NN ._SENT Lane_NP 1_CD ,_, serum_NN from_IN patients_NNS at_IN the_DT time_NN of_IN diagnosis_NN ;_: lanes_NNS 2_CD ,_, 3_CD ,_, and_CC 4_CD ,_, patterns_NNS obtained_VBD for_IN all_DT patients_NNS (_( n_NN =_SYM 10_CD )_) with_IN serum_NN taken_VBN on_IN days_NNS 30_CD ,_, 90_CD ,_, and_CC 180_CD ,_, respectively_RB ,_, after_IN treatment_NN with_IN SAG_NP ._SENT FIG._NN 3_CD ._SENT |_SYM Immunoblotting_NN with_IN soluble_JJ L._NP donovani_NN Immunoblotting_NN with_IN soluble_JJ L._NP donovani_NN antigen_NN with_IN the_DT alkaline_JJ phosphatase_NN system_NN from_IN a_DT patient_NN with_IN visceral_JJ leishmaniasis_NN ._SENT Lane_NP 1_CD ,_, serum_NN from_IN patients_NNS at_IN the_DT time_NN of_IN diagnosis_NN ;_: lanes_NNS 2_CD ,_, 3_CD ,_, and_CC 4_CD ,_, the_DT patterns_NNS obtained_VBN for_IN all_DT patients_NNS (_( n_NN =_SYM 10_CD )_) with_IN serum_NN taken_VBN on_IN days_NNS 30_CD ,_, 90_CD ,_, and_CC 180_CD ,_, respectively_RB ,_, after_IN treatment_NN with_IN miltefosine_NN ._SENT TABLE_NN 1_CD |_SYM Clinical_JJ and_CC laboratory_NN features_NNS of_IN patients_NNS with_IN visceral_JJ leishmaniasis_NN Parasitological_JJ methods_NNS have_VBP always_RB been_VBN considered_VBN first-choice_JJ procedures_NNS for_IN the_DT diagnosis_NN and_CC prognosis_NN of_IN leishmaniasis_NN due_JJ to_TO their_PP$ 100_CD %_NN specificities_NNS ,_, although_IN their_PP$ sensitivities_NNS may_MD vary_VB depending_VBG upon_IN the_DT experience_NN of_IN the_DT diagnostic_JJ team_NN ._SENT However_RB ,_, in_IN some_DT instances_NNS it_PP is_VBZ very_RB difficult_JJ to_TO demonstrate_VB the_DT presence_NN of_IN the_DT parasite_NN ,_, such_JJ as_IN in_IN patients_NNS with_IN mucocutaneous_JJ leishmaniasis_NN and_CC visceral_JJ leishmaniasis_NN ._SENT In_IN these_DT patients_NNS ,_, serodiagnosis_NN becomes_VBZ an_DT important_JJ alternative_NN for_IN demonstrating_VBG the_DT presence_NN of_IN the_DT parasite_NN ._SENT Specific_JJ serological_JJ techniques_NNS are_VBP based_VBN on_IN the_DT determination_NN of_IN antibodies_NNS produced_VBN against_IN the_DT circulating_VBG Leishmania-specific_JJ antigens_NNS ._SENT Both_DT clinical_JJ and_CC epidemiological_JJ data_NNS provide_VBP presumptive_JJ evidence_NN in_IN the_DT diagnosis_NN of_IN visceral_JJ leishmaniasis_NN ._SENT However_RB ,_, on_IN the_DT basis_NN of_IN these_DT same_JJ criteria_NNS ,_, other_JJ diseases_NNS must_MD be_VB considered_VBN in_IN the_DT differential_JJ diagnosis_NN ;_: among_IN these_DT are_NN malaria_NN ,_, typhoid_JJ fever_NN ,_, tuberculosis_NN ,_, and_CC leukemias_NNS ._SENT Definitive_JJ diagnosis_NN is_VBZ based_VBN on_IN demonstration_NN of_IN the_DT parasites_NNS ,_, which_WDT may_MD be_VB found_VBN in_IN aspirates_NNS of_IN the_DT spleen_NN (_( 98_CD %_NN of_IN the_DT aspirates_NNS are_VBP positive_JJ )_) ,_, (_( sternal_JJ )_) bone_NN marrow_NN (_( 85_CD %_NN of_IN the_DT aspirates_NNS are_VBP positive_JJ )_) ,_, and_CC liver_NN (_( 60_CD %_NN of_IN the_DT aspirates_NNS are_VBP positive_JJ )_) ._SENT Splenic_JJ aspiration_NN is_VBZ the_DT most_RBS reliable_JJ procedure_NN ,_, but_CC it_PP is_VBZ a_DT high-risk_JJ procedure_NN ._SENT Because_IN in_IN many_JJ cases_NNS demonstration_NN of_IN parasites_NNS is_VBZ difficult_JJ ,_, serological_JJ tests_NNS have_VBP provided_VBN a_DT useful_JJ alternative_NN ._SENT Among_IN the_DT most_RBS recently_RB described_VBN methods_NNS ,_, the_DT Western_JJ blot_NN technique_NN is_VBZ highly_RB sensitive_JJ and_CC specific_JJ and_CC provides_VBZ broader_JJR information_NN about_IN the_DT parasite_NN 's_POS antigenic_JJ profile_NN ._SENT In_IN the_DT present_JJ study_NN ,_, a_DT 65-kDa_JJ antigenic_JJ component_NN was_VBD recognized_VBN by_IN 100_CD %_NN of_IN serum_NN specimens_NNS from_IN patients_NNS with_IN clinically_RB and_CC pasitologically_RB confirmed_VBD visceral_JJ leishmaniasis_NN ._SENT It_PP was_VBD never_RB identified_VBN in_IN the_DT control_NN sera_NN tested_VBN (_( 100_CD %_NN specificity_NN )_) ._SENT There_EX was_VBD little_JJ variation_NN in_IN the_DT patterns_NNS of_IN the_DT bands_NNS recognized_VBN by_IN each_DT of_IN the_DT serum_NN specimens_NNS ._SENT Comparing_VBG our_PP$ results_NNS with_IN those_DT of_IN other_JJ groups_NNS ,_, we_PP found_VBD differences_NNS in_IN the_DT band_NN patterns_NNS recognized_VBN by_IN sera_NN from_IN patients_NNS with_IN visceral_JJ leishmaniasis_NN and_CC cutaneous_JJ leishmaniasis_NN using_VBG several_JJ Leishmania_NP isolates_NNS as_IN antigen_NN ._SENT The_DT studies_NNS of_IN Dos_NP Santos_NP et_FW al._FW showed_VBD reactivities_NNS with_IN the_DT 119-_CD and_CC 123-kDa_NP bands_NNS when_WRB an_DT extract_NN of_IN L._NP infantum_NN was_VBD used_VBN as_IN the_DT antigen_NN with_IN sera_NN from_IN patients_NNS with_IN visceral_JJ leishmaniasis_NN ._SENT In_IN additon_NP ,_, Rolland-Burger_NP et_FW al._FW found_VBD that_IN the_DT sera_NN of_IN patients_NNS with_IN visceral_JJ leishmaniasis_NN reacted_VBD to_TO a_DT 119-kDa_NP band_NN when_WRB L._NP infantum_NN was_VBD used_VBN as_IN the_DT antigen_NN ._SENT If_IN antibodies_NNS remain_VBP in_IN the_DT patient_NN for_IN years_NNS and_CC the_DT patient_NN 's_POS serum_NN has_VBZ a_DT Western_JJ blot_NN pattern_NN similar_JJ to_TO the_DT one_CD obtained_VBN at_IN the_DT time_NN of_IN diagnosis_NN ,_, then_RB serious_JJ doubts_NNS arise_VBP as_IN to_TO whether_IN a_DT patient_NN is_VBZ ever_RB completely_RB cured_VBD (_( i.e._FW ,_, the_DT patient_NN has_VBZ no_DT remaining_VBG parasites_NNS )_) or_CC whether_IN treatment_NN has_VBZ induced_VBN a_DT chronic_JJ subpatent_NN infection_NN ,_, leaving_VBG the_DT patient_NN susceptible_JJ to_TO relapse_VB later_RBR on_RB ;_: for_IN example_NN ,_, immunosuppression_NN can_MD lead_VB to_TO the_DT reemergence_NN of_IN active_JJ infection_NN ,_, as_RB in_IN the_DT case_NN of_IN visceral_JJ leishmaniasis_NN in_IN patients_NNS with_IN AIDS_NP ._SENT A_DT test_NN as_IN sensitive_JJ as_IN Western_JJ blotting_VBG may_MD be_VB able_JJ to_TO identify_VB immunosuppressed_JJ patients_NNS who_WP could_MD be_VB at_IN risk_NN of_IN a_DT relapse_NN of_IN leishmaniasis_NN ._SENT The_DT only_JJ difference_NN between_IN the_DT pre-_NN and_CC posttreatment_NN sera_NN of_IN the_DT groups_NNS treated_VBN with_IN SAG_NP and_CC miltefosine_NP was_VBD the_DT disappearance_NN of_IN all_DT protein_NN bands_NNS except_IN those_DT of_IN 65_CD and_CC 70_CD kDa_NNS ,_, respectively_RB ._SENT We_PP could_MD detect_VB a_DT 65-kDa_JJ polypeptide_NN in_IN 100_CD %_NN of_IN the_DT pretreatment_NN sera_NN from_IN kala_NN azar_NN patients_NNS ._SENT Vinayak_NP et_FW al._FW reported_VBN on_IN a_DT 63-_CD to_TO 68-kDa_JJ complex_NN which_WDT is_VBZ an_DT immunodominent_JJ surface_NN molecule_NN of_IN L._NP donovani_NNS that_WDT can_MD be_VB used_VBN as_IN an_DT immunoprophylactic_JJ agent_NN ._SENT Investigations_NNS have_VBP indicated_VBN that_IN major_JJ surface_NN glycoproteins_NNS with_IN molecular_JJ masses_NNS ranging_VBG from_IN 63_CD to_TO 68_CD kDa_NNS (_( known_VBN as_IN the_DT glycopeptide_NNS 63_CD [_SYM gp63_NN ]_SYM complex_JJ )_) are_VBP important_JJ ligands_NNS in_IN cell-to-cell_NN interactions_NNS and_CC cell_NN infectivity_NN ._SENT Vinayak_NP et_FW al._FW have_VBP shown_VBN that_IN promastigotes_NNS of_IN L._NP donovani_NNS use_VBP the_DT gp66_JJ molecule_NN not_RB only_RB for_IN identification_NN but_CC also_RB for_IN attachment_NN to_TO macrophages_NNS ._SENT Sera_NN from_IN patients_NNS with_IN confirmed_VBN leishmaniasis_NN have_VBP been_VBN shown_VBN to_TO identify_VB the_DT gp63_JJ complex_JJ molecule_NN in_IN Western_JJ immunoblots_NNS of_IN Leishmania_NP crude_JJ antigen_NN ._SENT Further_JJR work_NN is_VBZ needed_VBN to_TO define_VB the_DT possible_JJ value_NN of_IN the_DT 65-kDa_JJ band_NN as_IN a_DT prognostic_JJ indicator_NN ._SENT We_PP suggest_VBP that_IN the_DT band_NN of_IN 65_CD kDa_NNS could_MD be_VB useful_JJ for_IN diagnosis_NN of_IN Indian_JJ visceral_JJ leishmaniasis_NN ._SENT Furthermore_RB ,_, the_DT results_NNS of_IN our_PP$ studies_NNS suggest_VBP that_IN Western_JJ blotting_VBG could_MD be_VB a_DT sensitive_JJ technique_NN for_IN differentiation_NN between_IN the_DT acute_JJ and_CC chronic_JJ stages_NNS of_IN disease_NN ._SENT The_DT presence_NN of_IN bands_NNS of_IN 201_CD ,_, 193_CD ,_, 147_CD ,_, 100_CD ,_, 80_CD ,_, 70_CD ,_, 65_CD ,_, 50_CD ,_, 36_CD ,_, 20_CD ,_, and_CC 18_CD kDa_NN (_( Fig._NN and_CC )_) and_CC the_DT subsequent_JJ disappearance_NN of_IN all_DT bands_NNS except_IN those_DT of_IN 65_CD and_CC 70_CD kDa_NN during_IN the_DT course_NN of_IN treatment_NN suggest_VBP the_DT usefulness_NN of_IN Western_NP blotting_VBG in_IN making_VBG a_DT clear-cut_JJ prognosis_NN ._SENT The_DT most_RBS interesting_JJ observation_NN was_VBD the_DT disappearance_NN of_IN protein_NN bands_NNS unique_JJ to_TO both_CC the_DT SAG_NP and_CC the_DT miltefosine_JJ treatment_NN groups_NNS ,_, as_IN the_DT sera_NN of_IN all_DT patients_NNS in_IN the_DT trial_NN groups_NNS showed_VBD the_DT same_JJ band_NN patterns_NNS at_IN the_DT respective_JJ time_NN points_NNS ._SENT This_DT suggests_VBZ that_IN the_DT type_NN of_IN drug_NN used_VBN for_IN treatment_NN probably_RB has_VBZ a_DT bearing_NN on_IN the_DT immune_JJ response_NN ._SENT Our_PP$ data_NNS also_RB suggest_VBP that_IN Western_JJ blotting_VBG could_MD successfully_RB be_VB used_VBN when_WRB there_EX is_VBZ no_DT splenomegaly_NN ._SENT Western_JJ blotting_VBG could_MD also_RB be_VB a_DT prognostic_JJ tool_NN ,_, as_IN the_DT disappearance_NN or_CC reappearance_NN of_IN specific_JJ bands_NNS could_MD predict_VB cure_NN or_CC relapse_NN ._SENT Moreover_RB ,_, Western_JJ blotting_VBG analysis_NN showed_VBD a_DT large_JJ diversity_NN in_IN the_DT antibody_NN response_NN to_TO visceral_JJ leishmaniasis_NN and_CC permitted_VBN detection_NN of_IN antibodies_NNS to_TO Leishmania_NP in_IN serum_NN ._SENT 